Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CKPT Checkpoint Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CKPT
Price (delayed)
$4.15
Market cap
$361.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.29
Enterprise value
$328.09M
Checkpoint Therapeutics, Inc. ('Checkpoint') is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is
Highlights
CKPT's EPS has surged by 53% year-on-year and by 9% since the previous quarter
CKPT's gross profit is down by 40% YoY
Checkpoint Therapeutics's revenue has decreased by 40% YoY
Key stats
What are the main financial stats of CKPT
Market
Valuations
Earnings
Shares outstanding
87.02M
Market cap
$361.13M
Enterprise value
$328.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
21.33
Price to sales (P/S)
6,055.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,002.22
Revenue
$41,000
Gross profit
$41,000
Operating income
-$56.38M
Net income
-$56.51M
EBIT
-$56.51M
EBITDA
-$56.51M
Free cash flow
-$36.31M
Per share
Balance sheet
Liquidity
EPS
-$1.29
EPS diluted
-$1.29
Free cash flow per share
-$0.61
Book value per share
$0.19
Revenue per share
$0
TBVPS
$0.57
Total assets
$34.16M
Total liabilities
$17.87M
Debt
$0
Equity
$16.3M
Working capital
$16.3M
Debt to equity
0
Current ratio
1.91
Quick ratio
1.85
Net debt/EBITDA
0.58
Margins
Efficiency
Dividend
EBITDA margin
-137,822%
Gross margin
100%
Net margin
-137,822%
Operating margin
-137,500%
Return on assets
-430.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-346.8%
Return on sales
-137,822%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CKPT stock price
How has the Checkpoint Therapeutics stock price performed over time
Intraday
0%
1 week
-0.48%
1 month
2.72%
1 year
133.15%
YTD
29.69%
QTD
2.72%
Financial performance
How have Checkpoint Therapeutics's revenue and profit performed over time
Revenue
$41,000
Gross profit
$41,000
Operating income
-$56.38M
Net income
-$56.51M
Gross margin
100%
Net margin
-137,822%
The company's operating margin has shrunk by 108% YoY
CKPT's net margin has dropped by 79% year-on-year
CKPT's gross profit is down by 40% YoY
Checkpoint Therapeutics's revenue has decreased by 40% YoY
Price vs fundamentals
How does CKPT's price correlate with its fundamentals
Growth
What is Checkpoint Therapeutics's growth rate over time
Valuation
What is Checkpoint Therapeutics stock price valuation
P/E
N/A
P/B
21.33
P/S
6,055.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,002.22
CKPT's EPS has surged by 53% year-on-year and by 9% since the previous quarter
CKPT's price to sales (P/S) is 101% higher than its last 4 quarters average of 3013.7
Checkpoint Therapeutics's revenue has decreased by 40% YoY
Efficiency
How efficient is Checkpoint Therapeutics business performance
CKPT's return on sales has dropped by 79% year-on-year
The return on assets is up by 43% year-on-year and by 42% since the previous quarter
Dividends
What is CKPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CKPT.
Financial health
How did Checkpoint Therapeutics financials performed over time
The total assets is 91% more than the total liabilities
The total assets has soared by 185% YoY
The company's total liabilities fell by 20% YoY and by 11% QoQ
CKPT's debt is 100% smaller than its equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.